advertisement
 |
|
|
Top Stories
Dengvaxia is the first FDA-approved vaccine for dengue disease caused by all dengue virus serotypes for individuals ages 9 through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.
/ read more /
The companies will work together to develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology.
/ read more /
|
|
|
advertisement
 |
Subscribe
Subscribers can enjoy each full issue of Pharm Tech in print, or via Pharm Tech apps.
subscription offers |
 |
|
|
advertisement
 |
|
|
Industry News
MilliporeSigma event scheduled to recognize biotech challenges and support development potential.
/ read more /
FDA sent a warning letter to Dong Yuan Technology Co., Ltd. detailing CGMP violations including failure to follow laboratory and process controls.
/ read more /
More Industry News
|
|
|
advertisement
 |
|
Supplier News
The Vaccine Development and Bioprocess Cell Culture Technology Day will take place on May 16, 2019 in Baltimore, MD.
/ read more /
|
|
|
|
advertisement
Get Micro Testing with Macro Capabilities
View Eurofins Lancaster Laboratories' Microbiology virtual tour to see why our compliance, consulting and capacity are critical to ensuring the tiniest contamination does not become a big deal. We offer personalized study designs, the highest standard of data integrity, and largest scope of Micro Testing solutions to get it done on time and right the first time.
 Learn More |
|
|
|
Bio/Pharma News
The companies have entered into a sub-licensing agreement to develop products based on Dyadic’s C1 expression platform and Alphazymes’ enzyme technology.
/ read more /
A solar panel installation at Novo Nordisk's North Carolina facility was initiated in March 2019 as part of the company’s commitment to zero environmental impact globally.
/ read more /
More Bio/Pharma News
|
|
|
Regulatory News
The agency approved Benlysta (belimumab) intravenous infusion for treatment of children with systemic lupus erythematosus.
/ read more /
The agency is updating its warning requirements for eszopiclone, zaleplon, and zolpidem after reports of complex sleep behaviors.
/ read more /
More Regulatory News
|
|
|
UPCOMING WEBCASTs
Impact of New FDA Guidance on Bioanalytical Testing on Drug Development
Thursday, May 30, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
 Register now
Requirements for Fully-Integrated Service Offerings in a HPAPI and Cytotoxic Environment
Two Live Events: Tuesday, May 28, 2019, at 10am JST | 9pm EDT | 6pm PDT
Tuesday, May 28, 2019, at 5pm JST | 10am CEST
 Register now
Designing Amorphous Dispersion Formulations for Poorly Soluble Drugs
Thursday, May 23, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
 Register now
Technologies to De-Risk Biologic Candidates to Successfully Transition from Research to Clinic
Wednesday, May 22, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
 Register now
Geographic Advantage: Accelerating Clinical Supply in China and Global Trials
Thursday, May 9 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
 Register now
|
|
Events
June 3–6, 2019
June 12–13, 2019
June 18–20, 2019
more events |
|
|
eBOOKS
 |
The editors explore new tools for bio/pharma lab studies—such as robotics, augmented reality, and advanced instrumentation—as well as best practices for method development, multiple attribute monitoring, lab mixers, and raw material testing. |
|
|
|
|
|
